RANI Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 8.92%, SMA50 2.13%, SMA200 38.3%). The stock’s 14-day RSI is 56.7 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -64.34% below its high and over 256.59% above its low. Average 10-day trading volume of 834.50 thousand shares is below the 3-month average of 1.51 million, indicating normal recent market interest.

Rani Therapeutics Holdings, Inc. has 47.90 million shares outstanding. The public float is 33.62 million shares, elevated short interest at 0.27% of float. This equals 103.47 thousand shares. The short ratio is 0.15 days. Institutional investors hold 21.15% of the float. Insiders own 19.56%. Quiroga Moreno Isidoro holds 8.16 million shares, South Cone Investments Limited Partnership has 2.38 million shares and IMRAN MIR A has 2.08 million shares. Over the past six months, insider transactions show net selling. They sold 5.92 million shares across 2 transactions.

Rani Therapeutics Holdings, Inc. generated EPS of -$0.79 over the past year. Five-year average earnings growth is 4.78%. Wall Street analysts project EPS growth of 35.44% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.05. Next year's EPS is expected at $22.51. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $9.00. The high target offers 708.82% upside. The low target suggests 561.76% downside. The mean target is $10.25. This offers 653.68% upside. Rani Therapeutics Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 33.33%. The prior quarter beat by -5.26%. Over the last six quarters, Apple has recorded several small beats. These include -10.34% in August 06, 2024.

Rani Therapeutics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.20. This means the shares are trading below this model’s fair value.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) closed at $1.36 USD, losing -$0.01 (-0.73%) from the previous close of $1.37. The stock is currently mid-range between its 52-week high and low $0.39 and $3.87. With a market capitalization of about $99.27 million, Rani Therapeutics Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.43). Key stats such as the average daily volume over the past year has been around 1.50 million shares, volume is running light vs its 52-week average. Headquartered in San Jose, CA, Rani Therapeutics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Talat Imran, the company employs approximately 105 people and listed since July 30, 2021. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics.

Our AI price prediction model suggests that Rani Therapeutics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.88%, with price expected at $1.44 by March 16, 2026, within a range of $1.38 to $1.50 3-Month Outlook: Projected fall of -78.68%, reaching $0.29 by May 28, 2026, with a range of $0.20 to $0.38. 1-Year Outlook: Projected gain of 1053.68%, with price at $15.69 by March 02, 2027, within a range of $9.57 to $22.45.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares are flat 0.74% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Rani Therapeutics Holdings, Inc. trading at a premium to the broader market with a P/E of -1.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.81, suggesting 1062.5% upside. Our AI forecast model points to short-term strength (5.88% over two weeks), a medium-term fall (-78.68% over three months), and a longer-term gain (1053.68% over one year), with expected trading ranges indicating moderate volatility.

Rani Therapeutics Holdings, Inc. trades at a P/E ratio of -1.78, slightly below the S&P 500 average, with a price-to-sales ratio of 83.67 and a price-to-book ratio of -6.39 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.61, also above market averages.